Andere talen Monte Rosa Therapeutics, Inc.

Aandelen

GLUE

US61225M1027

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,32 ^USD	-5,17%		-3,97%	-5,84%

29/04	MONTE ROSA THERAPEUTICS, INC. : UBS geeft koopadvies	ZM
14/03	Monte Rosa Therapeutics nettoverlies over Q4 kleiner; aandelen dalen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Monte Rosa Therapeutics : AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer	03/04
Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline	14/03
Monte Rosa Therapeutics: Q4 Earnings Snapshot	14/03
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	14/03
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor	11/03
Monte Rosa Therapeutics, Inc. Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1b Pathway Inhibitor	11/03
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	31/01
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024	08/01
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from NASDAQ Biotechnology Index	15/12
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference	21/11
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Monte Rosa Therapeutics: Q3 Earnings Snapshot	09/11
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update	09/11
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases	07/11
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	27-10-23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules	26-10-23
Monte Rosa Therapeutics Partners With Roche in Targeting Cancer, Neurological Diseases; Shares Surge Pre-Bell	17-10-23
Monte Rosa Therapeutics : Company Call Presentation - October 17 2023	17-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Monte Rosa Therapeutics, Inc.

Aandelen

GLUE

US61225M1027

Andere talen

Filters